retatrutide news today october 2025 Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Retatrutide UK 2026: Phase 3

Posttreatment, all these manifestations were reduced

Nordstrand, T

April 2025: the Trump administration halted that Biden-era push to expand Medicare coverage for weight-loss drugs like Wegovy (semaglutide) and Zepbound (tirzepatide)

The therapeutic regimen for STZ-induced diabetic mice with early severe hyperglycemia ( n = 3, placebo group

There continues to be a gap between the number of prescriptions dispensed for ADMs (68.99% of patients filled an ADM GLP-1 RA prescription within 60 days) compared with AOMs (48.69% of patients filled an AOM GLP-1 RA prescription within 60 days)

Diabetologia 48:18821890 Hassing HA, Engelstoft MS, Sichlau RM et al (2016) Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor